Van Lanschot Kempen Investment Banking

Corporate Finance | Debt Advisory | Equity Capital Markets | Research | Trading | Structured Products
Part of @VLKCorporate
#lifesciences #realestate #fintech

[Van Lanschot Kempen Investment Banking @Kempen_Co]

This account is no longer active. Follow @VLKcorporate if you want to stay informed about Van Lanschot Kempen. Or take a look at our website: https://t.co/ObGpIDZ0j6

[Van Lanschot Kempen Investment Banking @Kempen_Co]

We acted as Joint Global Coordinator / Joint Bookrunner in #Hyloris IPO of €61.8 million. Its the first #IPO on #Euronext Brussels in 2020, and Kempen & Co's 8th overall transaction for European #lifesciences companies since the beginning of 2020.
https://t.co/LCfQO5Lu7T

[Van Lanschot Kempen Investment Banking @Kempen_Co]

The Oryzon Genomics’ Capital Increase of €20m is our 7th transaction for Euro #lifesciences companies in 2020 and our first ever for a Spanish LS company, underpinning our ambition to work with innovative LS companies in Europe. #biotech
https://t.co/Ki3sIZcdgs

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Our MD at Securities #AnnekaTreon commented yesterday about the current state of equity markets on #Bloomberg TV #stocks #economicrecovery #fiscalpolicy #equities #stockmarket #centralbanks #investments #investing #financialmarkets #finance https://t.co/7TAwEVKWCN

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Our Life Sciences analyst Suzanne van Voorthuizen today in De Telegraaf about 'the hunt for eternal fame with a coronavaccin': "Biotech companies feel, above all, a moral obligation to work on a solution"
https://t.co/PabeutL74S

[hollandbio @hollandbio]

Register now! During the webinar on June 26, ProQr's Daniel de Boer delves into the impact of COVID-19 on financing in the #lifesciences w/ Geraldine O'Keeffe (LSP), Arthur Franken (Gilde Healthcare), Krijn De Nood (Meatable) & Jan De Kerpel (Kempen & Co).
https://t.co/UPKTwzCLgY

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Kempen & Co acted as Joint Global Coordinator in BioInvent’s Capital Increase of SEK 487 million. This deal marks our sixth transaction in the Nordics region over the past 18 months, where we maintain a strong ambition to work with innovative companies.
https://t.co/RQnriomFao

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Head of Kempen's Real Estate Research Robert Woerdeman is sceptical about the modest price increase in the retail real estate stock market (article in Dutch)
https://t.co/JynSbxe9rB

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Analist Jaap Kuin comments in @telegraaf today about the retail property sector in The Netherlands - written by @JohanWiering and @PietervanED

@urw_group
https://t.co/LIGQlx3LyK

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Kempen & Co is pleased to announce it acted as Co-Manager the largest capital increase to date of its long-term client #argenx - setting a new landmark for European biotech by raising USD 750 million in gross proceeds
https://t.co/97kUsaDEGX

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Analyst Jaap Kuin in Dutch @FD_Nieuws about the price increase of @urw_group:
'Any snippet of positive news, for example about the reopening of shopping centers, can now lead to serious price increases. It mainly reflects the uncertainty in the market' https://t.co/K385skg9R7

[Van Lanschot Kempen Investment Banking @Kempen_Co]

@Trijntje_O, @KarsuDonmez en @Ams_Sinfonietta spelen in de Empty Concertgebouw Sessions, mogelijk gemaakt door Van Lanschot Kempen. Deze woensdag om 12:30 uur treedt @ruben_hein op https://t.co/7bzwQxzcHo
Klik hier voor de volledige planning: https://t.co/TwUaXIKOwz

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Life sciences analysts Suzanne van Voorthuizen and Alex Cogut were quoted in Dutch newspaper De Telegraaf about pricing of treatments and vaccins

https://t.co/pI0XjChCdp

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Our colleague Stan van Wersch explains in Dutch newspaper @nrc about doing his work as a trader with the #COVID2019NL restrictions: “I still cycle to the office everyday.”
https://t.co/tcaxIDaj09

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Our managing director Securities Anneka Treon discusses in The @FinancialTimes the role of banks in this crisis; behaving more like shock absorbers than shock amplifiers, as they were over 2007-2008.
https://t.co/fan7VBmPYs #banking #covid19 #economy #leverage

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Life Sciences analyst Suzanne van Voorthuizen comments in Dutch newspaper @nrc about the development of a vaccine for #Covid_19: ‘Investing in vaccines is an uncertain business and not always viable.’
https://t.co/JF0HLrwMY5

[Van Lanschot Kempen Life Sciences @KempenLS]

The search for a drug or vaccine for coronavirus is in full swing with more and more parties (like $BNTX) joining the global effort - with insights from our vaccines analyst Suzanne! #biotech #vaccines #coronavirus @BioNTech_Group

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Kempen analyst Alex Cogut comments on the development of #COVID19 tests in Dutch national newspaper @telegraaf: “German-Dutch biotech Qiagen probably the first with a test on the US market.” https://t.co/oMsEzT1mdc

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Kempen adviser in sale @TerraPay by @MahindraComviva to @prime_ventures and @PartechPartners. Joined by @IFC_org also participated in a capital increase to fund TerraPay’s global expansion. Congratulations to TerraPay’s founders @AmbarSur, @ram_terrapay, Ani Sane & Akbar Hussain

[Van Lanschot Kempen Investment Banking @Kempen_Co]

Happy Valentine’s Day from the heart of European Life Sciences! The 13th Kempen Life Sciences conference will be held on 21 & 22 April.
2019: almost 50 companies and over 100 investors
2020: it promises to be even busier. https://t.co/q5FpLb3qQQ